Log in
Research report
德邦证券-医药行业专题：耐药性高血压市场空间过百亿，新药研发捷报频传-230414
资格编号：S0120521080001邮箱： □全球耐药性高血压患者或超4亿，且目前无任何上市新药：在未来十年，全球将有近15亿成年人罹患高血压，其中约4.0亿RHTN患者。目前市场上并无任何专门为耐药性高血压开发的新药。 □虽然高血压领域相对成熟，但依旧有巨大未被满足需求：RHTN的主要危害是终末器官损害，包括心力衰竭、中风、缺血性心脏病和肾衰竭，RHTN是全球心血管病过早死亡的主要危险因素。美
Read full report →Related industries
No related institutions
Similar reports
- Knowing When to Stop: The Art of Making a Loop Converge
- Work-Study Programs Improve Young Women's Long-Term Labor Market Outcomes
- Sahel and West Africa Coastal Countries (SAWAC) Umbrella Program: 2026 Communications and Visibility Plan
- Scaling What Works: Integrated Social Protection Reforms for Poverty Reduction and Upward Mobility in Ghana